✦ LIBER ✦

Effects of beta-blockers on survival for patients with cirrhosis and refractory ascites

✍ Scribed by Gin-Ho Lo

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 632 KB
Volume: 53
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.23986

No coin nor oath required. For personal study only.

✦ Synopsis

Shorter duration and lower dose of peginterferon alfa-2a therapy results in inferior HBeAg seroconversion rates compared with the duration and dose of 48 weeks and 180 lg: NEPTUNE study.

📜 SIMILAR VOLUMES

Deleterious effects of beta-blockers on

Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites

✍ Mevlut Kurt 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 378 KB 👁 2 views

We read with great interest the article by Stepanova et al. 1 In this report from the United States with 10,582 eligible individuals (1.52% of whom were positive for hepatitis C virus [HCV] antibody [anti-HCV]), the rate of insurance coverage was significantly lower in patients with HCV infection (6

Deleterious effects of beta-blockers on

Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites

✍ Thomas Sersté; Christian Melot; Claire Francoz; François Durand; Pierre-Emmanuel 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 196 KB 👁 2 views

Beta-blockers may have a negative impact on survival in patients with cirrhosis and refractory ascites. The aim of this study was to evaluate the effect of the administration of beta-blockers on long-term survival in patients with cirrhosis and refractory ascites. We performed a single-center, obser

Beta-blockers in patients with cirrhosis

Beta-blockers in patients with cirrhosis and refractory ascites

✍ Albillos Agustín; Zamora Javier 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 296 KB 👁 2 views

We read with interest the reviews by Ghouri et al. 1 and Martinez et al. 2 Ghouri et al. analyzed the association of nonalcoholic fatty liver disease (NAFLD) with cardiovascular disease (CVD) and concluded that although a diagnosis of NAFLD should prompt diabetes screening, it is insufficient for co

Is this really the end of beta-blockers

Is this really the end of beta-blockers in patients with cirrhosis and refractory ascites?

✍ Thierry Thevenot; Jean-Paul Cervoni; Elisabeth Monnet; Frances Sheppard; Vincent 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 387 KB 👁 2 views

We read with interest the study by Sola `et al., 1 who found that 39 patients (67%) had a very alarming decrease in their serum sodium levels ! 5 mEq/L during terlipressin treatment for acute variceal bleeding (AVB). We, however, feel that some of their observations may require a closer look by the

Does cardiac dysfunction explain deleter

Does cardiac dysfunction explain deleterious effects of beta-blockers in cirrhosis and refractory ascites?

✍ Aleksander Krag; Flemming Bendtsen; Søren Møller 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 369 KB 👁 2 views

Beta-blockers have no effect on outcomes

Beta-blockers have no effect on outcomes in patients with cirrhosis and severe infections

✍ Arnaud Galbois; Vincent Das; Dominique Thabut; Eric Maury; Hafid Ait-Oufella; Ch 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 378 KB 👁 2 views